Compare Hims and Hers Health Inc (HIMS) vs Levi Strauss & Co. (LEVI) Price & Performance

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.

Levi Strauss (LEVI) trades at $19.51, down 4.97% today, amid a bearish technical signal but strong fundamentals. The company has consistently beaten earnings estimates, with Q3 2026 EPS of $0.48 exceeding expectations. Valuation metrics appear attractive with a P/E of 12.84 and P/S of 1.15, while profitability remains robust with a net income margin of 9.66% and ROE of 29.31%. Recent news highlights a new CFO appointment and positive analyst sentiment on denim demand.

The outlook is positive given earnings momentum and analyst consensus, with a price target of $27.80 implying significant upside. Risks include competitive pressures and recent cybersecurity incidents, but strong cash flow and dividend payments support shareholder value. Wall Street sentiment is bullish with 79% buy ratings.